Category 1 vs Category 2 vs 503A Bulks vs FDA-Approved: The Only Explainer You Need
💡 Key Takeaway
There are four different regulatory statuses for peptides, and the internet confuses them constantly. This is the definitive guide to what each one means, what it allows, and why the distinctions matter for your access to peptide therapy.
Every time the FDA makes a peptide announcement, the comments fill with people conflating four completely different things. “BPC-157 is legal now!” “Peptides are FDA-approved!” “Everything’s Category 1!” None of these statements are accurate, and the confusion has real consequences for how people access peptides safely.
Here’s the only explainer you need. Bookmark it.
The Four Statuses, Explained
| Status | What It Means | Can Pharmacies Compound It? | Example |
|---|---|---|---|
| Category 1 | On the 503A Bulks List — formally authorized for compounding | Yes, with a prescription | Thymosin Alpha-1, AOD-9604, GHK-Cu (topical), CJC-1295, Selank, Kisspeptin-10 |
| Off Category 2 | Removed from restricted list, but NOT yet on the Bulks List | Gray zone — restriction lifted but no formal authorization | BPC-157, TB-500, MOTS-C, KPV, DSIP, Semax, Epitalon (as of April 23, 2026) |
| Category 2 | Restricted — unresolved safety or efficacy concerns | No | GHRP-2, GHRP-6, Ipamorelin (still restricted) |
| FDA-Approved Drug | Approved as a pharmaceutical with labeled indications | N/A — available as manufactured drug, not compounded | Semaglutide (Wegovy/Ozempic), Tirzepatide (Mounjaro/Zepbound), Elamipretide (Barth syndrome) |
Category 1: The Green Light
Category 1 substances are on the official 503A Bulk Drug Substances List. This means a licensed 503A compounding pharmacy can legally prepare these substances with an individual prescription from a licensed prescriber. The compounded product must meet USP quality standards, and the pharmacy must comply with 503A regulatory requirements.
Current Category 1 peptides include thymosin alpha-1, AOD-9604, topical GHK-Cu, CJC-1295 (without DAC), selank, and kisspeptin-10, among others. These can be compounded today with appropriate prescriptions.
Off Category 2 (But Not Yet Category 1)
This is where most of the confusion lives. The twelve peptides removed from Category 2 on April 23, 2026 are in a regulatory middle ground. The restriction that prevented compounding has been lifted, but the FDA has not formally authorized compounding through the Bulks List.
What does a compounder do with a substance in this space? The honest answer is: it depends on the pharmacy’s risk tolerance and legal interpretation. Some 503A pharmacies have resumed compounding these substances, arguing that the absence of a Category 2 restriction means they’re permitted. Others are waiting for the PCAC review to provide formal authorization.
For seven of these peptides, that formal review is happening July 23–24. For the remaining five, it’s before February 2027.
Category 2: The Red Light
Category 2 substances have been flagged by the FDA as having unresolved safety or efficacy concerns that prevent their use in compounding. As of June 2026, the peptides remaining on Category 2 include GHRP-2, GHRP-6, and ipamorelin.
Licensed 503A pharmacies cannot compound Category 2 substances. There is no scheduled PCAC review for these peptides, and no timeline for their potential reclassification.
FDA-Approved Drugs: A Completely Different System
FDA drug approval is an entirely separate regulatory pathway from compounding. An FDA-approved drug has completed clinical trials demonstrating safety and efficacy for specific labeled indications. It has a standardized dosing label, is manufactured under cGMP conditions, and may be covered by insurance.
No peptide on the PCAC docket is an FDA-approved drug. Even if BPC-157 gets added to the 503A Bulks List, it will not be “FDA-approved” in the way semaglutide or tirzepatide are. It will be legally compoundable — a meaningful step, but a fundamentally different regulatory status.
The only peptide-adjacent substance to recently achieve FDA approval is elamipretide (SS-31), approved for Barth syndrome — a rare mitochondrial disease. Elamipretide traveled through the full NDA process with clinical trials, manufacturing standards, and labeled dosing.
Why These Distinctions Matter
The practical differences are significant:
- Insurance: FDA-approved drugs may be covered. Compounded substances are not.
- Quality standards: FDA-approved drugs are manufactured under cGMP. Compounded substances follow USP standards, which are less stringent.
- Dosing guidance: FDA-approved drugs have labeled dosing. Compounded substances are prescribed at the provider’s discretion.
- Liability: Prescribing FDA-approved drugs on-label carries standard malpractice coverage. Prescribing compounded substances carries additional liability considerations.
Understanding these distinctions helps you navigate the peptide landscape realistically — knowing what’s available, through which channels, with what level of quality assurance.
For real-time tracking of where each peptide stands in the regulatory process, see our PCAC Live Tracker.
BioPure Peptides
Research-grade peptides with batch-specific COAs. Category 1, off-Category 2, and research compounds all available.
Shop BioPure Peptides →POWER at checkoutFrequently Asked Questions
Category 1 peptides are on the 503A Bulks List and can be legally compounded with a prescription. Category 2 peptides are restricted due to unresolved safety or efficacy concerns and cannot be compounded.
As of April 23, 2026, BPC-157 is neither. It was removed from Category 2 but has not yet been added to the Category 1/503A Bulks List. It’s in a regulatory middle ground pending PCAC review on July 23, 2026.
The only peptide-adjacent substance with recent FDA drug approval is elamipretide (SS-31), approved for Barth syndrome. No peptide on the PCAC docket is FDA-approved. The 503A Bulks List authorization is a compounding pathway, not drug approval.
No. Compounded substances are not covered by insurance regardless of their 503A status. Only FDA-approved drugs with labeled indications are eligible for insurance coverage. Compounded peptides are cash-pay.
Related Articles
Not Sure Which Peptide Is Right for You?
Take our free 60-second quiz and get personalized recommendations based on your goals.
Take the Quiz →